Blog

Durham-based Immunotherapy firm Grid Therapeutics injects $4.5M funding – WRAL Tech Wire


WRAL Tech Wire

Durham-based Immunotherapy firm Grid Therapeutics injects $4.5M funding
WRAL Tech Wire
Grid Therapeutics, a Durham-based biotechnology company developing the first human derived targeted immunotherapy for cancer, has raised more than $4.5 million of a $5 million equity offering, according to a filing with the U.S. Securities and Exchange
Novartis Joins Harvard and Dana-Farber to Develop Delivery Systems for ImmunotherapiesImmuno-Oncology News



all 4 news articles »

2018-03-29 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.